Parent Terms |
Term With Siblings |
Child Terms |
|
(-)-secoisolariciresinol +
(1S,2R)-5-methoxy-1-methyl-2-(propylamino)tetralin
(1S,2R)-5-methoxy-1-methyl-2-(propylamino)tetralin hydrochloride
(R)-fluoxetine hydrochloride +
(S)-(-)-sulpiride An optically active form of sulpiride having (S)-configuration. The active enantiomer of the racemic drug sulpiride. Selective D2-like dopamine antagonist (Ki values are ~ 0.015. ~ 0.013, 1, ~ 45 and ~ 77 muM at D2, D3, D4, D1 and D5 receptors respectively).
(S)-duloxetine hydrochloride
(S)-fluoxetine hydrochloride +
4-(1-benzofuran-2-yl)pyridine
6alpha-methylprednisolone +
all-cis-5,8,11,14,17-icosapentaenoic acid +
atomoxetine hydrochloride
buclizine dihydrochloride
chlorprothixene hydrochloride
clomipramine hydrochloride
cyclobenzaprine hydrochloride
diphenhydramine hydrochloride
diphenhydramine salicylate
dothiepin hydrochloride +
escitalopram hydrobromide +
ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate
first generation antipsychotic +
fosaprepitant dimeglumine
gevotroline hydrochloride
kaempferol 3,7-di-O-alpha-L-rhamnoside
lithium citrate tetrahydrate
lofepramine hydrochloride
metoclopramide dihydrochloride monohydrate
metoclopramide hydrochloride +
mosapramine dihydrochloride
N-\{2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethyl\}-N-propylpropan-1-amine hydrochloride
palonosetron hydrochloride +
pipamperone dihydrochloride
promethazine hydrochloride
protriptyline hydrochloride
rolapitant hydrochloride (anhydrous) +
rolapitant hydrochloride hydrate
scopolamine hydrobromide trihydrate
second generation antipsychotic +
tetracyclic antidepressant +
tranylcypromine hydrochloride
tropisetron hydrochloride
vortioxetine hydrobromide
|
|
 |
Synonyms |
Exact Synonyms: |
N-{[(2S)-1-ethylpyrrolidin-2-yl]methyl}-2-methoxy-5-sulfamoylbenzamide
|
Related Synonyms: |
(-)-N-(((S)-1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide
;
(-)-sulpiride
;
(S)-(-)-5-aminosulfonyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide
;
Formula=C15H23N3O4S
;
InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)/t11-/m0/s1
;
InChIKey=BGRJTUBHPOOWDU-NSHDSACASA-N
;
S-(-)-N-(1-Ethyl-2-pyrrolidinomethyl)-2-methoxy-5-sulfamoylebenzamide
;
SMILES=CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O
;
levosulpirida
;
levosulpiride
;
levosulpiridum
|
Xrefs: |
CAS:23672-07-3
;
DrugBank:DB00391
;
Drug_Central:1577
;
KEGG:D07312
;
LINCS:LSM-5624
;
PMID:18186115
;
PMID:19165957
;
PMID:19452563
;
PMID:19488984
;
PMID:19795476
;
PMID:20438811
;
PMID:20656570
;
PMID:20850200
;
PMID:21223496
;
PMID:21615988
;
Patent:KR20110090142
;
Patent:US2011052700
;
Reaxys:3563418
;
Wikipedia:Levosulpiride
|
Cyclic Relationships: |
is_enantiomer_of CHEBI:64122 |
|